9 results about "HUMAN THYMUS" patented technology

Disclosed in the present invention are an antibody capable of binding to human thymic stromal lymphopoietin (hTSLP), a preparation method therefor and an application thereof. The anti-hTSLP antibody of the present invention can specifically bind to a hTSLP receptor, has a good effect of inhibiting the secretion of TARC by PBMC, and can be applied to the treatment of TSLP-related diseases, such as immune-mediated inflammatory diseases.

Provided are human anti-thymocyte globulin (ATG) products, and methods of making and using the same. In particular, the disclosure provides an ungulate-derived polyclonal immunoglobulin, comprising a population of fully human or substantially human immunoglobulins. The population of fully human or substantially human immunoglobulins specifically binds human thymocytes, T cells, B cells, and / or monocytes. Such compositions may be made by immunization of transgenic animals having a human Ig locus with human thymocytes. This method generates polyclonal immunoglobulin with yield, purity, and antigen specificity that enable the use of this product in medical applications.

In an aspect, a method of making a humanized animal includes providing an immune-deficient animal lacking mature T cells, B cells and NK cells; and injecting a population of human thymocytes into the immune-deficient animal to provide the humanized animal; wherein the population of human thymocytes are thymocytes collected from human thymus or thymus tissue; and wherein the humanized animal includes mature human T cells expressing human CD8 and human CD4. In another aspect, also included is a humanized animal prepared by the foregoing method.

The application belongs to the technical field of biological medicine, and particularly relates to a recombinant human thymosin beta 4 microneedle patch, a preparation method thereof and application. After a microneedle solution and a support layer solution are obtained, the microneedle solution is added into a microneedle mold, and then exhaust treatment is performed; after the exhaust treatment, the support layer solution is added into the microneedle mold to obtain a formed body; the formed body is dried, and after demolding, the recombinant human thymosin beta 4 microneedle patch is obtained; the temperature of the drying is < 40 DEG C. The recombinant human thymosin beta 4 microneedle patch prepared by the application has high drug loading, good forming, and high mechanical strength, can rapidly and continuously release most of the drugs in a short time, is beneficial to the percutaneous penetration of the Tbeta4 drug, and has a good promoting effect on wound healing.

The present application relates to the technical field of biology, in particular to human thymus tissue digestion solution and application thereof. The present application provides a preparation method of human thymus tissue digestion solution and human thymus tissue single cells, and the preparation method can obtain a human thymus tissue primary cell suspension with high viability, low fine nodule rate, high nucleated rate and less impurities, and can greatly improve the success rate of single cell sequencing experiment of human thymus tissue primary cells.

Provided are human anti-thymocyte globulin (ATG) products, and methods of making and using the same. In particular, the disclosure provides an ungulate-derived polyclonal immunoglobulin, comprising a population of fully human or substantially human immunoglobulins. The population of fully human or substantially human immunoglobulins specifically binds human thymocytes, T cells, B cells, and / or monocytes. Such compositions may be made by immunization of transgenic animals having a human Ig locus with human thymocytes. This method generates polyclonal immunoglobulin with yield, purity, and antigen specificity that enable the use of this product in medical applications.

This invention provides a human anti-thymocyte globulin (ATG) product, as well as a method for producing and using the same. [Solution] This disclosure provides polyclonal immunoglobulins derived from ungulates having a population of fully human or substantially human immunoglobulins. The population of fully human or substantially human immunoglobulins specifically binds to human thymocytes, T cells, B cells, and / or monocytes. Such compositions can be produced by immunizing transgenic animals having the human Ig locus with human thymocytes. This method produces polyclonal immunoglobulins with yield, purity, and antigen specificity that enable the use of this product in medical applications.

The present application provides an antibody molecule binding to human thymic stromal lymphopoietin (TSLP) and antigen-binding fragments thereof, and use of the antibody molecule or antigen-binding fragments thereof for preventing or treating TSLP high expression related purposes. The antibody molecule and antigen-binding fragments thereof of the present application can bind to human TSLP with high affinity, block the interaction between TSLP and its receptor, and significantly inhibit the secretion of chemokines such as CCL17, OPG, and dendritic cells, and can be used for treating diseases and disorders related to TSLP signaling and / or TSLP cell expression, such as inflammatory diseases or tumors.

The present invention discloses an antibody capable of binding to human thymic stromal lymphopoietin (hTSLP), as well as methods for preparing and using the same. The anti-human TSLP antibody of the present invention can specifically bind to the human TSLP receptor and has a potent inhibitory effect on TARC secretion by PBMCs, making it suitable for the treatment of TSLP-related diseases, such as immune-mediated inflammatory diseases.